Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 19 May 2017

Esperite (ESP) announces that Genoma SA filed appeal to the decision ruled by the Swiss Court

Esperite N.V.    

Published: 13:19 CEST 19-05-2017 /GlobeNewswire /Source: Esperite N.V. / : ESP /ISIN: NL0009272137

Esperite (ESP) announces that Genoma SA filed appeal to the decision ruled by the Swiss Court

 

 

Genoma has filed appeal to the decision of liquidation taken on May 4th 2017. Genoma considers this decision arbitrary due to the circumstances of the commercial and legal relationship with Premaitha.

 

 

Zutphen, The Netherlands, 19 May 2017

 

Genoma has concluded with Premaitha an agreement in March 15th 2015 for the supply of the genetic test Iona. The implementation of this contract implied significant investment specifically related to the use of the IONA Kits. Genoma represented 65% of Premaitha's business in 2015/16.

 

Genoma was forced to discontinue using the Premaitha Iona test some weeks after the serious legal claim against Premaitha's technology by Illumina (Patent Infringement). Premaitha has not been able to demonstrate that the Iona test doesn't infringe Illumina's patents.

 

Genoma blocked payments to Premaitha, a total of +€900k for several reasons:

  • A considerable amount has been claimed for failure in the supply;
  • Illumina sued Genoma for patent infringement because of the use of Premaitha's Iona;
  • Premaitha never offered valid support for defence despite they were selling a patent infringing product.

 

The British supplier sent several summons for payment and finally obtained a court decision ruling for the bankruptcy of Genoma officially on May 4th 2017. The official register was updated on the 9th of May 2017.

 

About ESPERITE

ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

 

To learn more about ESPERITE Group, or to book an interview with CEO Frederic Amar: +31 575 548 998 - ir@esperite.com or visit the websites at

www.esperite.com and www.genoma.com.

 



PR Genoma



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Esperite N.V., Piet Heinstraat 11a, Zutphen 7204 JN, The Netherlands
If you would like to unsubscribe and stop receiving these e-mails click here.